Merck May Sell Mature Drug Portfolio for $15B

Reuters sources are reporting that Merck is considering selling a large portfolio of off-patent drugs with a potential $15B pricetag.

Merck is working with an investment bank on the off-patent assets sale, which may attract interest from generic drugmakers, Reuters reports.

This news comes as Merck nears the potential sale of its $14B consumer healthcare business.

Merck's asset disposal efforts are in line with recent moves by drugmakers to sell off non-core divisions in order to better focus on core products.

 Read the Reuters press release

 

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments